Since January 2020 Elsevier has created a COVID - 19 resource centre with free information in English and Mandarin on the novel coronavirus COVID - 19 . The COVID - 19 resource centre is hosted on Elsevier Connect , the company ' s public news and information website . Elsevier hereby grants permission to make all its COVID - 19 - related research that is available on the COVID - 19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories , such as the WHO COVID database with rights for unrestricted research re - use and analyses in any form or by any means with acknowledgement of the original source . These permissions are granted for free by Elsevier for as long as the COVID - 19 resource centre remains active . Journal Pre - proof Contact pattern , current immune barrier , and pathogen virulence determines the optimal strategy of further vaccination Xiaohao Guo , Ziyan Liu , Shiting Yang , Zeyu Zhao , Yichao Guo , Guzainuer Abudurusuli , Shanlu Zhao , Ge Zeng , Shixiong Hu , Kaiwei Luo , Tianmu Chen PII : S2468 - 0427 ( 23 ) 00003 - 9 DOI : https : / / doi . org / 10 . 1016 / j . idm . 2023 . 01 . 003 Reference : IDM 352 To appear in : Infectious Disease Modelling Received Date : 13 November 2022 Revised Date : 5 January 2023 Accepted Date : 8 January 2023 Please cite this article as : Guo X . , Liu Z . , Yang S . , Zhao Z . , Guo Y . , Abudurusuli G . , Zhao S . , Zeng G . , Hu S . , Luo K . & Chen T . , Contact pattern , current immune barrier , and pathogen virulence determines the optimal strategy of further vaccination , Infectious Disease Modelling ( 2023 ) , doi : https : / / doi . org / 10 . 1016 / j . idm . 2023 . 01 . 003 . This is a PDF file of an article that has undergone enhancements after acceptance , such as the addition of a cover page and metadata , and formatting for readability , but it is not yet the definitive version of record . This version will undergo additional copyediting , typesetting and review before it is published in its final form , but we are providing this version to give early visibility of the article . Please note that , during the production process , errors may be discovered which could affect the content , and all legal disclaimers that apply to the journal pertain . Â© 2023 The Authors . Publishing services by Elsevier B . V . on behalf of KeAi Communications Co . Ltd . Title : Contact pattern , current immune barrier , and pathogen virulence 1 determines the optimal strategy of further vaccination 2 Author names : 3 Xiaohao Guo 1 # , Ziyan Liu 2 # , Shiting Yang 1 # , Zeyu Zhao 1 # , Yichao Guo 1 , 4 Guzainuer Abudurusuli 1 , Shanlu Zhao 2 , Ge Zeng 2 , Shixiong Hu 2 * , Kaiwei Luo 2 * , 5 Tianmu Chen 1 * 6 Affiliations : 7 1 . State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics , 8 School of Public Health , Xiamen University , Xiamen City 361102 , Fujian 9 Province , Peopleâ€™s Republic of China 10 2 . Hunan Provincial Center for Disease Control and Prevention , 405 Furong 11 Middle Road Section One , Kaifu District , Changsha City 410001 , Hunan 12 Province , Peopleâ€™s Republic of China 13 # X . G . , Z . L . , S . Y . , Z . Z . contributed equally to this work ; 14 Emails : 15 Xiaohao Guo : guo3 . 1415926536 @ qq . com 16 Ziyan Liu : 1715773383 @ qq . com 17 Shiting Yang : yst3393 @ 163 . com 18 Zeyu Zhao : 381597586 @ qq . com 19 Yichao Guo : 564931539 @ qq . com 20 Guzainuer Abudurusuli : 748693650 @ qq . com 21 Shanlu Zhao : 1654919009 @ qq . com 22 J o u r n a l P r e - p r o o f Ge Zeng : 244870450 @ qq . com 23 Shixiong Hu : 379788967 @ qq . com 24 Kaiwei Luo : 87616498 @ qq . com 25 Tianmu Chen : 13698665 @ qq . com 26 # These authors contributed equally to this study 27 * Correspondence : 28 Shixiong Hu 29 Hunan Provincial Center for Disease Control and Prevention 30 405 Furong Middle Road Section One , Kaifu District , Changsha City 410001 , 31 Hunan Province , Peopleâ€™s Republic of China 32 Email : 379788967 @ qq . com 33 Telephone : 135 0847 6422 34 Kaiwei Luo 35 Hunan Provincial Center for Disease Control and Prevention 36 405 Furong Middle Road Section One , Kaifu District , Changsha City 410001 , 37 Hunan Province , Peopleâ€™s Republic of China 38 Email : 87616498 @ qq . com 39 Telephone : 158 7490 9523 40 Tianmu Chen 41 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics , 42 School of Public Health , Xiamen University 43 4221 - 117 South Xiangâ€™an Road , Xiangâ€™an District , Xiamen , Fujian Province , 44 J o u r n a l P r e - p r o o f Peopleâ€™s Republic of China 45 Email : chentianmu @ xmu . edu . cn , 13698665 @ qq . com 46 Telephone : 13661934715 47 Abstract 48 Background 49 The current outbreak of novel coronavirus disease 2019 has caused a serious 50 disease burden worldwide . Vaccines are an important factor to sustain the 51 epidemic . Although with a relatively high - vaccination worldwide , the decay of 52 vaccine efficacy and the arising of new variants lead us to the challenge of 53 maintaining a sufficient immune barrier to protect the population . 54 Method 55 A case - contact tracking data in Hunan , China , is used to estimate the contact 56 pattern of cases for scenarios including school , workspace , etc , rather than 57 ordinary susceptible population . Based on the estimated vaccine coverage and 58 efficacy , a multi - group vaccinated - exposed - presymptomatic - symptomatic - 59 asymptomatic - removed model ( VEFIAR ) with 8 age groups , with each partitioned 60 into 4 vaccination status groups is developed . The optimal dose - wise vaccinating 61 strategy is optimized based on the currently estimated immunity barrier of 62 coverage and efficacy , using the greedy algorithm that minimizes the cumulative 63 cases , population size of hospitalized and fatality respectively in a certain future 64 interval . Parameters of Delta and Omicron variants are used respectively in the 65 optimization . 66 J o u r n a l P r e - p r o o f Results 67 The estimated contact matrices of cases showed a concentration on middle ages , 68 and has compatible magnitudes compared to estimations from contact surveys in 69 other studies . The VEFIAR model is numerically stable . The optimal control 70 vaccination strategy requires immediate vaccination on the un - vaccinated high - 71 contact population of age 30 - 39 to reduce the cumulative cases , and is stable with 72 different basic reproduction numbers ( ğ‘… 0 ) . As for minimizing hospitalization and 73 fatality , the optimized strategy requires vaccination on the un - vaccinated of both 74 aged 30 - 39 of high contact frequency and the vulnerable older . 75 Conclusion 76 The objective of reducing transmission requires vaccination in age groups of the 77 highest contact frequency , with more priority for un - vaccinated than un - fully or 78 fully vaccinated . The objective of reducing total hospitalization and fatality 79 requires not only to reduce transmission but also to protect the vulnerable older . 80 The priority changes by vaccination progress . For any region , if the local contact 81 pattern is available , then with the vaccination coverage , efficacy , and disease 82 characteristics of relative risks in heterogeneous populations , the optimal dose - 83 wise vaccinating process will be obtained and gives hints for decision - making . 84 Keywords : vaccine , allocation strategy , SARS - CoV - 2 , optimal control , immune 85 barrier , contact pattern , greedy algorithm 86 87 Introduction 88 J o u r n a l P r e - p r o o f At the end of 2019 , the novel coronavirus disease 2019 caused by severe acute 89 respiratory syndrome coronavirus 2 ( SARS - CoV - 2 ) first broke out in Wuhan , 90 China , and then swept across the world at an extremely rapid pace . As of 91 September 27 , 2022 , a total of 612 , 236 , 677 confirmed cases globally with 92 6 , 514 , 397 deaths had been reported by WHO 1 . Although several targeted 93 interventions have been implemented globally to contain the spread of the new 94 crown epidemic , the situation remains challenging as dominant variant strain 95 updates one by another . A safe and effective new - coronavirus vaccine is essential 96 to reduce transmission , ICUs , mobility and even end the outbreak of novel 97 coronavirus . Although there was a high vaccine coverage with fully vaccinations , 98 the vaccine efficacy ( VE ) in preventing infection is not satisfying . The emergence 99 of new variants poses a challenge to the effectiveness of the new - coronavirus 100 vaccine . The US Centers for Disease Control and Prevention began 101 recommending that all people who receive the Johnson & Johnson vaccine 102 receive a booster at least 2 months in advance 2 . Regular vaccinations help to 103 maintain antibody levels in the body and a booster shot of the new - coronavirus 104 vaccine may be the general trend . 105 Vaccines are a powerful tool in the current fight against the epidemic , but 106 with limited supplies , it is important to consider who should be prioritized for 107 vaccination and what vaccine distribution scheme should be implemented to 108 maximize health and economic benefits . WHO believes that those who could 109 benefit from safe and effective SARS - CoV - 2 vaccines should have access as 110 J o u r n a l P r e - p r o o f quickly as possible , starting with those at the highest risk of serious disease or 111 death 3 . As age is one of the risk factors for serious SARS - CoV - 2 infections and 112 death 4 , the elderly population is the most frequently cited priority target group 5 6 113 7 8 , but studies have also suggested that there is a strong moral case for giving 114 children priority for vaccination to protect the elderly 9 10 . Depending on the 115 objectives , several studies have suggested that priority should be given to 116 vaccinating the elderly population against the new coronavirus to reduce the 117 number of seriously ill patients and reduce mortality , and to the young population 118 to reduce the spread of the new coronavirus 11 12 . According to the effectiveness 119 and availability of the vaccine , it has been suggested that in cases of low vaccine 120 effectiveness and low vaccine availability , it is preferable to allocate the vaccine 121 to the higher age groups first ; in cases of high vaccine effectiveness and high 122 vaccine coverage , it is preferable to allocate the vaccine to the lower age 9 . As the 123 dynamics of the novel coronavirus pneumonia epidemic and the status of vaccine 124 supply continue to change , we should adjust our immunization strategy promptly 125 and identify priority target groups for vaccination . 126 Most of those studies considers static allocation of vaccination instead of a 127 dose - wise or time - varying vaccination process . Besides , the dynamical model of 128 SIR ( susceptible - infectious - removed ) , SEIR ( susceptible - exposed - infectious - 129 removed ) , and SEIAR ( susceptible - exposed - symptomatic / asymptomatic 130 infectious - removed ) does not precisely represent the natural history of SARS - 131 J o u r n a l P r e - p r o o f CoV - 2 , where a considerable pre - symptomatic infectious stage acts in 132 tranmission . 133 To have a better understanding of the impact on age - specific contact patterns 134 and immune barrier in the optimal vaccination strategy , this study analyzed local 135 exposure patterns and vaccine effectiveness using case - contact data from Hunan 136 Province , simulated the transmission of age groups and computed the optimal 137 dose - wise vaccination strategy . A vaccinated - exposed - presymptomatic - 138 symptomatic / asymptomatic - removed ( VEFIAR ) model is developed with a pre - 139 symptomatic stage for better approximation of natural history of SARS - CoV - 2 . 140 The dose - wise vaccination process is considered for optimization instead of a 141 static vaccine distribution optimization for capturing more details . Unlike the 142 most previous studies that simulates the age - grouped models on contact data of 143 health people , this study considers the different behaviors between health people 144 and cases by using data of close contact to construct the special contact pattern of 145 cases and simulates . 146 Materials and methods 147 Data collection 148 A real world scenario of Delta variant outbreak in Hunan Province , China during 149 July 22 , 2021 to August 15 , 2021 is choosed to illustrate the optimal vaccination 150 strategy . Among all of 129 cases in this outbreak , 124 cases and their 13915 close 151 contacts or sub - close contacts have finished a survey of close contact tracing . The 152 information collected including age , sex , date of last contact , locations where the 153 J o u r n a l P r e - p r o o f last contact taken placed , relation between case and close contacts , exposure 154 ranking , and vaccination status . The definition and standard for judgement of 155 close contact and sub - close contact is given by the Diagnosis and Treatment 156 Protocol for Novel Coronavirus Pneumonia , Version 8 13 . Data of all cases and 157 their close contacts are provided by Hunan Provincial Centers for Disease Control 158 and Prevention . 159 Statistical Analysis 160 We first evaluate the vaccine coverage in population by inspecting the four 161 vaccination status : none , un - fully vaccinated , fully vaccinated , and booster 162 vaccinated of close contacts in contact data . 163 The total attack rates ( TARs ) are computed for people in different age 164 groups and people with different vaccination status . To handle the uncertainty of 165 the collected data , we use bootstrap 14 to construct the empirical distribution of all 166 these TARs . We performed the bootstrap 10000 times on the contact data , with 167 each bootstrapped data set containing equally 10000 contacts . Each of those 168 bootstrapped data sets produces an 8 Ã— 4 matrix of TAR in age groups ( in rows ) 169 and vaccine groups ( in columns ) . Based on those resampled TARs , we depict the 170 distribution of TAR in age groups and vaccine groups in box - plot respectively . 171 The following logistic regression model is used for analyzing odds ratios ( OR ) of 172 age groups and vaccination status groups : 173 ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡ ( ğ”¼ { ğ‘Œ | ğ— = ğ± } ) = [ 1 , ğ— ğ‘‡ ] ğ›ƒ { ğ‘Œ | ğ— = ğ± } âˆ¼ binomial distribution 174 J o u r n a l P r e - p r o o f where ğ‘™ğ‘œğ‘”ğ‘–ğ‘¡ ( ğ‘¥ ) = ğ‘™ğ‘› ( ğ‘¥ 1âˆ’ğ‘¥ ) is the canonical link function of binomial 175 distribution ; ğ”¼ denote the expectation operation of random variables ; ğ‘Œ is the 176 0 - 1 random variable of whether a close contact is infected ( 1 represent infected , 0 177 represent un - infected ) ; ğ— is a 4 Ã— 1 random vector with its entries be 4 factors : 178 vaccination status , contact age , contact gender and exposure ranking ; ğ± is an 179 observation of ğ— ; ğ›ƒ is a 5 Ã— 1 vector of coefficients ( include coefficient of 180 intercept ) . 181 Based on the coefficient of contact age and vaccination status , the the odds 182 ratio ( OR ) are computed for different age and vaccination groups by : 183 ğ‘‚ğ‘… = ğ‘’ ğ‘¥ 1ğ‘‡ ğ›½Ì‚âˆ’ğ‘¥ 0ğ‘‡ ğ›½Ì‚ 184 where ğ›½Ì‚ is the fitted parameter vector of the logistic model ; ğ‘¥ 0 is the properties 185 of reference population ; ğ‘¥ 1 is the properties of target population . ( Note that the 186 exposure ranking and the contact gender are the same in ğ‘¥ 0 and ğ‘¥ 1 , and they are 187 vanished by ğ‘¥ 1 âˆ’ ğ‘¥ 2 ) 188 Contact pattern analysis 189 We use a contact matrix to describe the current contact pattern . The ğ‘–ğ‘— - entry of 190 the contact matrix is defined as the average number of contacts in group ğ‘— that 191 one individual in group ğ‘– would produce during a period of one day . A bipartite 192 graph model is developed to describe the properties of the contact matrix . We 193 first construct the contact data matrix by simply fills all the case - contact data 194 pairs in . Then , based on the bipartite graph model , three methods of least square , 195 J o u r n a l P r e - p r o o f weighted least square , and maximum likelihood , are developed for estimating the 196 contact matrix . The contact matrices are also estimated using the subset of case - 197 contact data which contact occurs in specific scenarios of public transports , 198 amusement , school , household , hospital , working area , service industry , 199 community , catering industry , uncategorized setting , and empty settings in 200 original data respectively . 201 Model development 202 To evaluate the effectiveness of vaccination and heterogeneity among population , 203 a multi - group vaccinated - exposed - pre - symptomatic - symptomatic - asymptomatic - 204 removed ( ğ‘‰ğ¸ğ¹ğ¼ğ´ğ‘… ) model is developed . The vaccine efficacy ( ğ‘‰ğ¸ ) is 205 considered as coefficients of reducing susceptibility . In simulation , we use the 206 odds ratio versus people of average age and average vaccination status , fitted 207 using the logistic regression , to replace the coefficients ( 1 â€“ ğ‘‰ğ¸ ) in the newly 208 infection term . 209 Modeling details including assumptions , interpretation of variable and 210 parameters are all presented in supplementary table S1 to S4 and section 2 . 1 of 211 the supplementary material . 212 The ordinary differential equations of the model is given by : 213 J o u r n a l P r e - p r o o f ğ‘‘ğ‘‰ ğ‘–ğ‘— ğ‘‘ğ‘¡ = âˆ’ğœ† ğ‘– ( 1 âˆ’ ğ‘‰ğ¸ ğ‘–ğ‘— ) ğ‘‰ ğ‘–ğ‘— ğ‘‘ğ¸ ğ‘–ğ‘— ğ‘‘ğ‘¡ = ğœ† ğ‘– ( 1 âˆ’ ğ‘‰ğ¸ ğ‘–ğ‘— ) ğ‘‰ ğ‘–ğ‘— âˆ’ ( 1 âˆ’ ğ‘ ğ‘–ğ‘— ) ğœ” ğ‘–â€² ğ¸ ğ‘–ğ‘— âˆ’ ğ‘ ğ‘–ğ‘— ğœ” ğ‘– ğ¸ ğ‘–ğ‘— ğ‘‘ğ¹ ğ‘–ğ‘— ğ‘‘ğ‘¡ = ( 1 âˆ’ ğ‘ ğ‘–ğ‘— ) ğœ” ğ‘–â€² ğ¸ ğ‘–ğ‘— âˆ’ ğœ” ğ‘–â€³ ğ¹ ğ‘–ğ‘— ğ‘‘ğ¼ ğ‘–ğ‘— ğ‘‘ğ‘¡ = ğœ” ğ‘–â€³ ğ¹ ğ‘–ğ‘— âˆ’ ğ›¾ ğ‘– ğ¼ ğ‘–ğ‘— ğ‘‘ğ´ ğ‘–ğ‘— ğ‘‘ğ‘¡ = ğ‘ ğ‘–ğ‘— ğœ” ğ‘– ğ¸ ğ‘–ğ‘— âˆ’ ğ›¾ ğ‘–â€² ğ´ ğ‘–ğ‘— ğ‘‘ğ‘… ğ‘–ğ‘— ğ‘‘ğ‘¡ = ğ›¾ ğ‘–â€² ğ´ ğ‘–ğ‘— + ğ›¾ ğ‘– ğ¼ ğ‘–ğ‘— 214 where subscript ğ‘– = 1 , 2 , â‹¯ , 8 and ğ‘— = 0 , 1 , 2 , 3 denote the subgroups of age ğ‘– 215 and vaccination status ğ‘— ; ğœ† ğ‘– is the infection force acted on each individual in age 216 group ğ‘– produced by all infected population , and is defined as : 217 ğœ† ğ‘– = âˆ‘ ğ›½ ğ‘˜ğ‘– ğ‘› ğ‘˜ = 1 [ âˆ‘ ( ğ¼ ğ‘˜ğ‘— + ğœ…ğ´ ğ‘˜ğ‘— + ğœ… â€² ğ¹ ğ‘˜ğ‘— ) 3 ğ‘— = 0 ] , 218 where ğœ… and ğœ… â€² denote different transmissibility of asymptomatic and pre - 219 symptomatic populations . 220 Then , ğœ† ğ‘– ğ‘‰ ğ‘–ğ‘— is the newly infection rate of subgroup ğ‘–ğ‘— . And by considering the 221 vaccine efficacy inside age group ğ‘– , we multiplies each ğ‘‰ ğ‘–ğ‘— by a constant 222 vaccine efficacy coefficient 1 âˆ’ ğ‘‰ğ¸ ğ‘–ğ‘— . In practice , we use the data estimated odd 223 ratios ğ‘‚ğ‘… ğ‘–ğ‘— versus average population ( Table S7 ) to replace 1 âˆ’ ğ‘‰ğ¸ ğ‘–ğ‘— . That is , 224 the newly infection term is obtained as : âˆ’ğœ† ğ‘– ( 1 âˆ’ ğ‘‰ğ¸ ğ‘–ğ‘— ) ğ‘‰ ğ‘–ğ‘— = âˆ’ğœ† ğ‘– ğ‘‚ğ‘… ğ‘–ğ‘— ğ‘‰ ğ‘–ğ‘— . 225 To introduce the impact of contact patterns in the multi - group ğ‘‰ğ¸ğ¹ğ¼ğ´ğ‘… 226 model , the transmission rate coefficients ğ›½ ğ‘–ğ‘— are formularized as the products of 227 J o u r n a l P r e - p r o o f the number of daily average contacts , the probability of infection after single one - 228 time contact , and the susceptibility of people in the ğ‘— - th group , that is , 229 ğ›½ ğ‘–ğ‘— ğ‘ ğ‘– = ğ‘ ğ‘—ğ‘– ğ‘ğœ ğ‘— , 230 where ğ‘ ğ‘—ğ‘– is the ğ‘—ğ‘– - th entry of contact matrix ; ğ‘ is the probability of infection 231 after a single one - time contact ; ğœ ğ‘— is the susceptibility of group ğ‘— . 232 The basic reproduction number ( ğ‘… 0 ) computed by next - generation method 233 is a function of all ğ›½ ğ‘–ğ‘— and other parameters . With the assumption of 234 decomposition of ğ›½ ğ‘–ğ‘— and the assumption of equal susceptibility in age groups , 235 ğ‘… 0 is indeed a function of contact matrix C , probability of contact infection ğ‘ , 236 and all other parameters and the disease - free equilibrium . In our simulation , the 237 probability of infection ğ‘ is solved from the pre - defined ğ‘… 0 for simulation , and 238 all ğ›½ ğ‘–ğ‘— are recovered from the contact matrix ğ¶ and ğ‘ . 239 The grouped ğ‘‰ğ¸ğ¹ğ¼ğ´ğ‘… model is tested by simulating with different ğ‘… 0 . The 240 contact pattern involved for recovering all ğ›½ ğ‘–ğ‘— from ğ‘… 0 is set to be the contact 241 matrix estimated via maximum likelihood estimation ( MLE ) , and the first patient 242 ( indicator ) is set to be in age group 30 to 39 , with fully vaccinated status , just as it 243 was in this outbreak . For each simulated ğ‘… 0 , the daily incidence rates are shown 244 for each vaccine group , and the total attack rates in 100 - days are shown for each 245 age and vaccine group . 246 Table 1 interprets all parameters defined in the multi - group ğ‘‰ğ¸ğ¹ğ¼ğ´ğ‘… 247 model . 248 J o u r n a l P r e - p r o o f Optimization for dose - wise vaccinating process 249 The optimization of dose - wise vaccinating process is indeed an optimal control 250 problem that can be transformed into a nonlinear programming problem ( NLP ) 15 251 by discretizing the controls , and solved by a variety of numerical optimization 252 methods . Typically , one may use back propagation for sub - gradient , and use 253 stochastic gradient descent method for optimizing . However , in real world , the 254 vaccinating process is not always parallel with abundant vaccines , rather than a 255 small amount of step - wise vaccinating process . For this consideration , we use the 256 greedy algorithm 16 to approximate the optimal vaccinating process under the 257 current vaccine coverage . The function to be minimized ( the objective function ) 258 is constructed as the cumulative number of cases by taking weighted summation 259 of time integrals of all ğ¹ ğ‘–ğ‘— and ğ´ ğ‘–ğ‘— during the 14 - days simulation . This 260 objective can be also interpreted as if we assigned this dose to such group , then 261 what reduction of cumulative cases are expected within the next 14 - days . Other 262 indicators of concerned , like morbidities and ICUs , can be obtained by weighting 263 the cumulative cases by group - relevant morbidities and ICU ratios . 264 The directional derivative is introduced as an index for the effectiveness of 265 the current dose vaccinated in different groups . The optimal step - wise vaccinating 266 strategy is then obtained by minimizing the directional derivative for each dose . 267 We visualized the optimal vaccine process by showing the population - size curves 268 of each age groups and vaccine groups . Detail profiles of the optimization 269 problem can be found in chapter 4 in the supplementary material . 270 J o u r n a l P r e - p r o o f All analysis and simulation are completed using MATLAB 2021b . 271 Result 272 Epidemiology characteristics and vaccine efficacy 273 The boxplot in Figure 1 ( a ) shows the different distribution of bootstrapped 274 total attack rates ( TARs ) in age groups and vaccine groups . There is no clear 275 trend of TAR in age groups , and does not change much among groups of middle 276 age , mainly because mixture effects of factors like different vaccine coverage 277 among age groups . The medians of TARs in all age groups are around 10 % . 278 TARs in the youngest age group and the oldest age group are lowest , which can 279 be explained by its lower contact rate . One can conclude TAR in one group is 280 greater than the other group with 95 % confidence by inspecting whether the 281 notches of boxplots overlaps . 282 For the vaccine groups in Figure 1 ( b ) , similarly by inspecting the notches , 283 we conclude with 95 % confidence that the median of TAR decrease by doses . 284 The coefficients fitted in the logistic regression model are all significantly 285 differ from 0 , except the contact gender ( Table S5 ) . The odds ratios versus the 286 un - vaccinated aged greater than 70 and the odds ratios versus the average age 287 ( 38 . 6 year old ) and average vaccine status are then computed using the fitted 288 coefficients ( Table 2 and Table S7 ) . 289 J o u r n a l P r e - p r o o f Analysis of contact pattern 290 The estimated contact matrix in Figure 2 ( b ) showed a small adjustment compared 291 with the contact data matrix in Figure 2 ( a ) . Both of the matrices showed a 292 concentration of contacts in diagonal entries and middle entries , which indicates 293 people in the same age group are more likely to make contact , and people in 294 middle ages are more likely to contact with others ( middle ages are more likely to 295 have children and parents to feed ) . Our matrices are coherent with the result of 296 the contact matrix in Wuhan and Shanghai , two cities in China 17 18 . The scenario - 297 specific contact matrices are presented in the supplementary material . 298 Optimal vaccinating process 299 The optimal vaccinating process is computed for different basic reproduction 300 number ğ‘… 0 = 1 , 2 , â‹¯ , 12 , different objective function weights of cumulative 301 cases , hospitalization , and fatality , and different parameters of variants Delta and 302 Omicron in reference 19 . We included all those results in the supplementary 303 material , and present only the result of Delta variant with ğ‘… 0 = 8 . 304 Figure 3 answers the question which age - vaccine group should be 305 vaccinated first , and showed how the priority of each age - vaccination group 306 change with doses , which gives a hint for future vaccine distribution . 307 In the computed optimal vaccinating process , three objective functions give 308 a coherent result which requires an immediate vaccination to those un - vaccinated 309 in the age group 30 to 39 ( Figure 3 ( a ) ) . This can be seem from the upper - right 310 J o u r n a l P r e - p r o o f sub - figure of age 30 to 39 , where the population size of at least vaccinated one 311 dose increased since the first dose ( x - axis = 0 ) , which means the un - vaccinated of 312 30 to 39 should be firstly vaccinated into the un - fully vaccinated group . Since the 313 age group 30 to 39 is of highest contact frequency with other groups , this strategy 314 could be interpreted as to reduce transmissions at an early stage . The objective 315 function of hospitalization and fatality , however , requires vaccination on the 316 oldest just after the age group of 30 to 39 are all covered with at least one dose 317 for higher ğ‘… 0 , and interchange order for lower ğ‘… 0 . This can be interpreted as to 318 begin reducing cases in high - risk populations when the transmission is somehow 319 controlled . 320 Despite the age , and focusing only on the vaccine groups , we found that the 321 un - vaccinated group should be vaccinated first to reduce the cumulative cases , 322 since , in all 8 sub - figures in Figure 3 ( a ) , the un - vaccinated are always first to be 323 vaccinated . 324 Discussion 325 Validity of close - contact matrix 326 In transmission simulation of air - borne disease like SARS - Cov - 2 , the age - 327 specific contact pattern is typically obtained from a survey of susceptible 328 population 20 . However , in this paper , the dataset of close - contact survey from 329 reported cases is firstly used to reflect the contact pattern of cases . This 330 estimation may be more suitable for simulating transmissions if significant 331 J o u r n a l P r e - p r o o f proportion of cases behave differ from the susceptible population , and that is the 332 current circumstances with public health and social measures ( PHSMs ) . 333 Our contact matrix estimation method considers the nature of connection 334 between two sub - groups by using a bipartite graph model . The resulted 335 estimation is robust for lack of cases ( participants ) in some age groups , i . e . the 336 circumstances that one or more rows of the contact data matrix contains little or 337 even no cases . This method solves the problem by calibrating such rows by its 338 symmetric columns . 339 The estimated contact matrices are consistent with results from an age - 340 specific contact surveyed by a study 18 , suggesting the feasibility of simulating 341 scenarios like sex , age , school , workplace by our estimated setting - specific 342 contact matrices . The concentration of contacts in middle age groups reveals 343 some characteristics of social functions in each population . 344 The disadvantage of case - contact data may be described as the difficulty of 345 its collection . Without a comprehensive case - wise survey , it is almost impossible 346 to construct a reliable contact matrix . Also , the number of cases can not be too 347 small , which makes it not always available at the beginning of an outbreak . 348 The immune barrier 349 By November 2021 , 50 % of people has been fully vaccinated in China 21 . We 350 found a relatively high vaccine coverage with 27 . 5 % of none vaccinated , 13 . 4 % 351 of vaccinated but un - fully , 59 . 1 % of fully vaccinated and very little booster 352 J o u r n a l P r e - p r o o f vaccinated in Hunan Province , leading the local area an immune barrier to control 353 the outbreak of SARS - CoV - 2 . The vaccine effectiveness had been increased with 354 the enhancing of vaccination doses , which is similar to reports in study 22 . 355 The immune barrier is of great importance to restrain transmission and 356 reducing social burden of hospitalization and morbidities . In epidemics , new 357 variants , decay of vaccine efficacy lead us a great challenge of maintaining 358 immune barrier of population within a relatively high level . As a new variants 359 become dominant , epidemiologists must check whether the current immune 360 barrier is adequate or not . On the point of view of optimization , we can always 361 compute optimal vaccination strategy and observe its effectiveness using 362 parameters of new variants , vaccine efficacy and the equivalence coverage of 363 decay . 364 Validity of Multi - group transmission model 365 The multi - group ğ‘‰ğ¸ğ¹ğ¼ğ´ğ‘… model consider heterogeneity of age and vaccination 366 status in population , which is a improvement of our previous studies 23 . The 367 model is simulated with real - world vaccine coverage and immunity using data 368 from Hunan Province . 369 The simulation gives highest incidence rate in people aged 30 to 39 years 370 old , which was consistent with a 27 . 56 % proportion reported cases in this age 371 group . This concentration is similar to a study indicating that transmission mainly 372 occurred in middle and old people 23 . 373 J o u r n a l P r e - p r o o f Effectiveness of the optimized vaccination process 374 The dose - wise vaccination optimization strategy present a time varying decision - 375 making progress , showing the changing priority about which age group and 376 vaccination status group should firstly be vaccinated in further vaccination . 377 Sometimes it may be more instructive than the results of optimized static 378 distribution in 9 , especially for developing countries with small vaccinating 379 capacity stream . The greedy algorithm we used is simpler on dose - wise idea , and 380 easier implemented than other studies that transform the optimal control problem 381 of real - time vaccination optimization to nonlinear programming problems ( NLPs ) 382 24 . The optimization method we used can be easily extended for decision 383 variables of higher dimensions , considering heterogenity of age - vaccination - 384 region subgroups . Although the optimization method of greedy algorithm can 385 hardly found the global minimum for general optimization problems , however , its 386 objective of optimize efficiency for each dose meets real - world needs of reduce 387 the epidemic costs at any time within and before endemics . 388 The objective function decrease smoothly under the computed optimal 389 vaccination strategy , which support the stability of the optimization . 390 In practice , if local contact pattern is obtained , then we can optimize the 391 further vaccination strategy under current immune barrier for epidemic indices . 392 J o u r n a l P r e - p r o o f Limitations 393 Vaccination efficacy decays over time , however , such consideration involving 394 assumptions about the speed of local vaccination capacity , and the decay curve of 395 the vaccine efficacy . The decay of individual vaccine efficacy can be introduced 396 into the dynamical model by using the equivalent decay of vaccinated population 397 size in dynamic models . However , we can omitted this for the amazing 398 vaccination speed in Hunan . 399 Since the contact pattern and odds ratios are estimated using data collected 400 in Hunan Province , the extension of the optimized vaccination process may 401 limited to Hunan Province . Regional contact pattern and other parameters are 402 recommended when extending similar optimization to other regions . 403 The optimal solution given by greedy algorithm is more likely be a local 404 optimizer rather than a global optimizer . 405 In practice , the high - risk occupations should be vaccinated with priority , 406 however , it is not considered in the age - vaccination grouped model . 407 Conclusion 408 The resulting dose - wise strategy illustrate the changing priority about which age 409 group and vaccination status group should firstly be vaccinated in further 410 vaccination , which may give us constructive suggestion to the decision . Under the 411 current vaccine coverage and vaccine efficacy , the objective of reducing 412 transmission requires vaccination in age groups of highest contact with other 413 J o u r n a l P r e - p r o o f groups , with more priority for un - vaccinated than un - fully or fully vaccinated . 414 However , the objective of reducing total hospitalization and fatality requires not 415 only to reduce of transmission but also to protect the vulnerable population of the 416 older . 417 The contact pattern estimated by the case - contact data depicts the behavior 418 of cases rather than the un - infected population , and will be more suitable for 419 transmission simulation , especially for diseases where significant proportion of 420 patients behaves differ from un - infected population . In simulation of emerging 421 infectious diseases , although the data - driven contact pattern is hardly available , 422 the uncertainty of differences between contact pattern that cause actually 423 transmission and the contact pattern of un - infected population in ordinary period 424 must be considered with suitable calibrations . 425 The optimization method of greedy algorithm is easy to extended for 426 heterogeneity consideration of partitioning the whole population into more 427 heterogeneous sub - groups . 428 Consent for publication 429 Not applicable . 430 Ethics approval and consent to participate 431 Not applicable . 432 Availability of data and materials 433 J o u r n a l P r e - p r o o f A PDF file contains modeling details and profiles of numerical solutions . All 434 codes and figures are available in authorâ€™s github : 435 https : / / github . com / 1095912686 / SupplementaryCodesForOptimalVaccinationStr 436 ategyInHunanForSARS - CoV - 2 . 437 Funding 438 This study was partly supported by The National Key Research and Development 439 Program of China ( 2021YFC2301604 ) , The research project on education and teaching 440 reform of undergraduate universities of Fujian Province , China ( FBJG20210260 ) , The Self - 441 supporting Program of Guangzhou Laboratory ( Grant No . SRPG22 - 007 ) , The Research on 442 the precise prevention and control system of SARS - Cov - 2 ( Grant No . 35022022YJ07 , Topic 443 No . 2022YJ - 3 ) . The funders of the study had no role in study design , data 444 collection , data analysis , data interpretation or writing of the report . 445 Conflict of interest 446 The authors declare that they have no competing interests . 447 Authorâ€™s contributions 448 XHG conceived and designed the study , conducted the analysis and the 449 framework of the study , wrote the first draft of the manuscript , wrote 450 MATLAB codes . 451 ZYL provided original data , wrote the first draft of the manuscript , improved this 452 research and edited the manuscript . 453 J o u r n a l P r e - p r o o f STY conducted the analysis and the framework of the study , wrote the first draft 454 of the manuscript . 455 ZYZ conceived and designed the study , conducted the analysis and the 456 framework of the study , wrote the first draft of the manuscript , improved this 457 research and edited the manuscript . 458 YCG wrote the first draft of the manuscript , improved this research and edited 459 the manuscript . 460 GA wrote the first draft of the manuscript , improved this research and edited the 461 manuscript . 462 SLZ provided original data , wrote the first draft of the manuscript , improved this 463 research and edited the manuscript . 464 GZ provided original data , wrote the first draft of the manuscript , improved this 465 research and edited the manuscript . 466 SXH conceived and designed the study , provided original data , wrote the first 467 draft of the manuscript , improved this research and edited the manuscript . 468 KWL provided original data , improved this research and edited the manuscript . 469 TMC conceived and designed the study , improved this research and edited the 470 manuscript . 471 All authors contributed to revising subsequent versions of the manuscript . All 472 authors read and approved the final manuscript . 473 J o u r n a l P r e - p r o o f Acknowledgements 474 Not applicable . 475 Reference 476 1 Organization , W . H . WHO Coronavirus ( COVID - 19 ) Dashboard , < https : / / covid19 . who . int / > ( 477 2 Cohn , B . A . , Cirillo , P . M . , Murphy , C . C . , Krigbaum , N . Y . & Wallace , A . W . SARS - CoV - 2 vaccine 478 protection and deaths among US veterans during 2021 . Science 375 , 331 - 336 , 479 doi : 10 . 1126 / science . abm0620 ( 2022 ) . 480 3 Organization , W . H . Coronavirus disease ( COVID - 19 ) : Vaccine access and allocation , 481 < https : / / www . who . int / news - room / questions - and - answers / item / coronavirus - disease - ( covid - 482 19 ) - vaccine - access - and - allocation > ( 2021 ) . 483 4 Gao , Y . - D . et al . Risk factors for severe and critically ill COVID - 19 patients : A review . Allergy 76 , 484 428 - 455 ( 2020 ) . 485 5 Noh , E . B . , Nam , H . K . & Lee , H . Which Group Should be Vaccinated First ? : A Systematic Review . 486 Infect Chemother 53 , 261 - 270 ( 2021 ) . 487 6 Matrajt , L . et al . Optimizing vaccine allocation for COVID - 19 vaccines shows the potential role 488 of single - dose vaccination . Nature Communications 12 , 3449 ( 2021 ) . 489 7 Moore , S . , Hill , E . M . , Dyson , L . , Tildesley , M . J . & Keeling , M . J . Modelling optimal vaccination 490 strategy for SARS - CoV - 2 in the UK . PLoS Comput Biol 17 , e1008849 ( 2021 ) . 491 8 Zhao , Z . - Y . et al . The optimal vaccination strategy to control COVID - 19 : a modeling study in 492 Wuhan City , China . Infect Dis Poverty 10 , 140 ( 2021 ) . 493 9 Matrajt , L . , Eaton , J . , Leung , T . & Brown , E . R . Vaccine optimization for COVID - 19 : Who to 494 vaccinate first ? Science Advances 7 , eabf1374 , doi : 10 . 1126 / sciadv . abf1374 ( 2021 ) . 495 J o u r n a l P r e - p r o o f 10 Giubilini , A . , Savulescu , J . & Wilkinson , D . COVID - 19 vaccine : vaccinate the young to protect the 496 old ? J Law Biosci 7 , lsaa050 ( 2020 ) . 497 11 Buckner , J . H . , Chowell , G . & Springborn , M . R . Dynamic prioritization of COVID - 19 vaccines 498 when social distancing is limited for essential workers . Proc Natl Acad Sci U S A 118 ( 2021 ) . 499 12 Bubar , K . M . et al . Model - informed COVID - 19 vaccine prioritization strategies by age and 500 serostatus . Science 371 , 916 - 921 ( 2021 ) . 501 13 Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia , Version 8 , 502 < http : / / www . gov . cn / zhengce / zhengceku / 2021 - 04 / 15 / content _ 5599795 . htm > ( 2021 ) . 503 14 Givens , G . H . & Hoeting , J . A . Computational statistics . Vol . 703 ( John Wiley & Sons , 2012 ) . 504 15 Betts , J . T . Practical Methods for Optimal Control and Estimation Using Nonlinear Programming , 505 Second Edition . Second edn , ( Society for Industrial and Applied Mathematics , 2010 ) . 506 16 Balaman , Å . Y . in Decision - Making for Biomass - Based Production Chains ( ed Åebnem YÄ±lmaz 507 Balaman ) 185 - 236 ( Academic Press , 2019 ) . 508 17 Zhang , J . et al . Changes in contact patterns shape the dynamics of the COVID - 19 outbreak in 509 China . Science 368 , 1481 - 1486 , doi : 10 . 1126 / science . abb8001 ( 2020 ) . 510 18 Zhang , J . et al . The impact of relaxing interventions on human contact patterns and SARS - CoV - 511 2 transmission in China . Science Advances 7 , eabe2584 , doi : 10 . 1126 / sciadv . abe2584 ( 2021 ) . 512 19 COVID - 19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with 513 and Without Booster Doses During Periods of Delta and Omicron Variant Emergence , author = . 514 MMWR Morb Mortal Wkly Rep 71 , 132 - 138 ( 2022 ) . 515 20 Tran Kiem , C . et al . SARS - CoV - 2 transmission across age groups in France and implications for 516 control . Nature communications 12 , 6895 , doi : 10 . 1038 / s41467 - 021 - 27163 - 1 ( 2021 ) . 517 J o u r n a l P r e - p r o o f 21 Data , O . W . i . Coronavirus ( COVID - 19 ) Vaccinations , < https : / / ourworldindata . org / covid - 518 vaccinations > ( 2022 ) . 519 22 Mrak , D . et al . Heterologous vector versus homologous mRNA COVID - 19 booster vaccination 520 in non - seroconverted immunosuppressed patients : a randomized controlled trial . Nature 521 Communications 13 , 5362 ( 2022 ) . 522 23 Zhao , Z . - Y . et al . A five - compartment model of age - specific transmissibility of SARS - CoV - 2 . Infect 523 Dis Poverty 9 , 117 ( 2020 ) . 524 24 Han , S . et al . Time - varying optimization of COVID - 19 vaccine prioritization in the context of 525 limited vaccination capacity . Nat Commun 12 , 4673 ( 2021 ) . 526 25 Chen , T . et al . Feasibility of COVID - 19 control from a pandemic to endemic . 527 doi : 10 . 21203 / rs . 3 . rs - 1283643 / v1 ( 2022 ) . 528 529 J o u r n a l P r e - p r o o f Graphical Abstract 530 531 532 J o u r n a l P r e - p r o o f Figure Captions 533 Fig 1 . Total Attack Rates ( TARs ) . ( a ) TAR in different age groups ; ( b ) TAR in 534 different vaccination status groups . The method of bootstrap is used to illustrate the 535 distribution of TAR in specific groups . 10000 times of bootstrap of the close 536 contact data is performed , with bootstrap sample size equals 10000 . Each 537 bootstrapped data set produces a sample matrix of TAR ( of each age and 538 vaccination status group ) . 539 540 541 J o u r n a l P r e - p r o o f Fig 2 . Contact Data Matrix and Contact Matrix . ( a ) Contact Data Matrix filled with 542 contact data . ( b ) Contact Matrix estimated by maximum likelihood estimation 543 ( based on a bipartite graph model ) . The model and other estimation of contact 544 matrix are presented in the supplementary material . 545 546 547 J o u r n a l P r e - p r o o f Fig 3 . Optimized Vaccinating Strategy Under Current Contact Pattern and Vaccine 548 Coverage . With R _ 0 = 8 and parameters of Delta variant . ( a ) : minimize cumulative 549 cases ; ( b ) : minimize hospitalization ; ( c ) : minimize fatality . For each of ( a ) , ( b ) , ( c ) , 550 8 sub - figures represent the optimal vaccination process in 8 age groups . The x - axis 551 represent the vaccination process in doses ; the y - axis represents the population size 552 of four vaccination status . The purple line with circles denote the population size 553 of booster vaccinated ; the blue line with triangles denote the population size of at 554 least fully - vaccinated ( including fully vaccinated and booster vaccinated ) ; the red 555 line with squares denote the population size of at least vaccinated ( including un - 556 fully vaccinated , fully vaccinated , and booster vaccinated ) . These lines depicts how 557 population size , i . e . the coverage changes with optimized vaccination process . The 558 line increased from the first dose gives the specific information about which 559 population should be vaccinated first . 560 J o u r n a l P r e - p r o o f 561 Tables 562 Table 1 . Parameter Profiles 563 J o u r n a l P r e - p r o o f Parameter Interpretation Value ( Range ) Unit Source ğ‘› number of age groups 8 1 self - defined ğ‘ ğ‘–ğ‘— daily average number of contact in age group ğ‘— that a individual in age group ğ‘– will produce estimated in Figure 2 person â‹… day âˆ’1 data estimated ğ›½ ğ‘–ğ‘— transmission rate - day âˆ’1 â‹… person âˆ’1 compute by ğ‘ ğ‘–ğ‘— and ğ‘… 0 ğ‘‚ğ‘… ğ‘–ğ‘— the average vaccine efficacy of age group ğ‘– in vaccination group ğ‘— - 1 by fitted logistic regression model ğœ† ğ‘– force of infection acted to group ğ‘– - day âˆ’1 compute from ğ›½ ğ‘–ğ‘— , ğ¸ ğ‘–ğ‘— , ğ´ ğ‘–ğ‘— and ğ¼ ğ‘–ğ‘— 1 / ğœ” ğ‘–ğ‘— average latent period of those asymptomatic cases of vaccination status ğ‘— in age group ğ‘– 3 day reference 25 1 / ğœ” ğ‘–ğ‘—â€² average latent period of those pre - symptomatic cases of vaccination status ğ‘— in age group ğ‘– 3 day reference 25 1 / ğœ” ğ‘–ğ‘—â€³ average duration from pre - symptomatic ğ¹ ğ‘–ğ‘— to symptomatic ğ¼ ğ‘–ğ‘— 2 day reference 25 ğ‘ ğ‘–ğ‘— probability that one exposed individual of vaccination status ğ‘— in age group ğ‘– will become symptomatic 0 . 31 for un - vaccinated ; 0 . 62 for vaccinated 1 reference 25 1 / ğ›¾ average infectious period of those symptomatic of vaccination status ğ‘— in age group ğ‘– 5 day reference 25 1 / ğ›¾ â€² average infectious period of those asymptomatic of vaccination status ğ‘— in age group ğ‘– 7 day reference 25 J o u r n a l P r e - p r o o f Parameter Interpretation Value ( Range ) Unit Source ğœ… relative transmission ability of asymptomatic cases 0 . 35 1 reference 25 ğœ… â€² relative transmission ability of pre - symptomatic cases 0 . 63 1 reference 25 564 J o u r n a l P r e - p r o o f Table 2 . Odds Ratio for Age and Vaccination Groups ( versus â‰¥ 70 , un - vaccinated ) non - vaccinated un - fully vaccinated fully vaccinated booster vaccinated 0 to 9 7 . 4867 e - 01 3 . 8872 e - 01 2 . 0182 e - 01 1 . 0479 e - 01 10 to 19 7 . 8028 e - 01 4 . 0513 e - 01 2 . 1034 e - 01 1 . 0921 e - 01 20 to 29 8 . 1322 e - 01 4 . 2223 e - 01 2 . 1922 e - 01 1 . 1382 e - 01 30 to 39 8 . 4755 e - 01 4 . 4006 e - 01 2 . 2848 e - 01 1 . 1863 e - 01 40 to 49 8 . 8333 e - 01 4 . 5863 e - 01 2 . 3813 e - 01 1 . 2364 e - 01 50 to 59 9 . 2063 e - 01 4 . 7800 e - 01 2 . 4818 e - 01 1 . 2886 e - 01 60 to 69 9 . 5949 e - 01 4 . 9818 e - 01 2 . 5866 e - 01 1 . 3430e âˆ’ 01 â‰¥ 70 1 . 0000 e + 00 5 . 1921e âˆ’ 01 2 . 6958e âˆ’ 01 1 . 3997e âˆ’ 01 565 566 567 J o u r n a l P r e - p r o o f Declaration of interests â˜’ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper . â˜ The authors declare the following financial interests / personal relationships which may be considered as potential competing interests : J o u r n a l P r e - p r o o f